RxDoctor Payments Data

Danielle Glick

Physician Assistant · Indianapolis, INNPI 1104230531

Payments from drug & device makers

$6,950in general payments, 2019–2025

Across 290 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • MDD US Operations, LLC$553
  • Takeda Pharmaceuticals U.S.A., Inc.$535
  • Gilead$530
  • Johnson & Johnson$521
  • Sanofi$506
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$6,83198%
  • Education$1182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,950 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$11,376
Medicare patients
115
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$80,635
LinzessLinaclotide109$75,189
XifaxanRifaximin12$37,726
Mesalamine19$16,339
TrulancePlecanatide22$15,736
Dexlansoprazole DrDexlansoprazole32$6,095
Sucralfate23$4,641
Ursodiol18$3,616
Colestipol Hcl37$3,301
Pantoprazole Sodium222$2,518
Omeprazole230$2,512
Dicyclomine Hcl96$2,338
Azathioprine19$1,819
Famotidine139$1,693
Lubiprostone14$1,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,532$155,824121 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$203$53,46234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →